TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from 4DMedical Ltd ( (AU:4DX) ) is now available.
4DMedical Limited has announced the commercial rollout of its CT:VQ™ technology at Stanford University, marking the first U.S. Academic Medical Centre to adopt the FDA-cleared technology. This move is part of a broader strategy to establish CT:VQ™ as a new standard of care in pulmonary imaging across leading U.S. institutions. Additionally, 4DMedical, in partnership with AstraZeneca, is expanding its Lung Health Screening Program in Brazil to five more hospitals, significantly increasing the program’s reach and impact. These developments are expected to accelerate clinical adoption and generate real-world evidence, positioning 4DMedical as a leader in respiratory imaging technology.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company that specializes in advanced imaging and artificial intelligence for respiratory care. The company offers a range of software solutions, including the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and the CT:VQ™ solution, which aim to improve the detection, diagnosis, and monitoring of lung diseases. These solutions are delivered through a Software-as-a-Service (SaaS) model, integrating into existing hospital infrastructure to enhance physician productivity and patient care.
Average Trading Volume: 8,041,472
Technical Sentiment Signal: Buy
Current Market Cap: A$882.6M
See more insights into 4DX stock on TipRanks’ Stock Analysis page.